Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Reduction of Pftk1 as a novel therapeutic target for Parkinson's Disease
EF 2018-19
Résumé
A New Target for Parkinson's Disease
Over 100,000 Canadians suffer from Parkinson’s disease (PD), a neurodegenerative disease that causes a number of clinical presentations including rigidity and tremors. There are currently medications to help with symptom management, but a cure has yet to be found. One of the hallmarks of PD are aggregates called Lewy bodies, which are found in the brain, and we’ve recently learned that Lewy bodies are mostly made up of a protein called a-Synuclein (a-Syn). The levels of a-Syn are directly related to disease severity; with higher levels we see increased severity in both humans and model organisms. Based on these findings, lowering a-Syn levels will likely enable us to treat PD patients much better by stopping or slowing disease progression. It is difficult to suppress a-Syn directly, so we’re focusing on a protein that controls a-Syn levels, PFTAIRE protein kinase 1 (Pftk1), which can be targeted with traditional pharmaceuticals. When Pftk1 is inhibited a-Syn levels are reduced. A recently produced mouse model, completely lacking the gene to produce Pftk1, shows no sign of abnormalities which may indicate that chronic loss of Pftk1 would be safe for humans. Our first goal is to study these mice to confirm that chronic loss is safe and effective at lowering a-Syn levels. Our second goal is to determine whether partial loss of Pftk1 is sufficient to improve PD presentation by using a PD mouse model that contains half of the genes that produce Pftk1. This partial loss will be a better representation of what a pharmaceutical inhibition would look like. If these results are promising our next step will be to identify and test pharmaceutical Pftk1 inhibitors, with the ultimate goal of finding a medication for PD patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
415368
Name
O'Connor Kaela
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Reduction of Pftk1 as a novel therapeutic target for Parkinson's Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alpha-Synuclein; Cdk14; Nervous System; Neurobehaviour; Neuropathology; Parkinson'S Disease; Pftk1
Abstract
A New Target for Parkinson's Disease
Over 100,000 Canadians suffer from Parkinson’s disease (PD), a neurodegenerative disease that causes a number of clinical presentations including rigidity and tremors. There are currently medications to help with symptom management, but a cure has yet to be found. One of the hallmarks of PD are aggregates called Lewy bodies, which are found in the brain, and we’ve recently learned that Lewy bodies are mostly made up of a protein called a-Synuclein (a-Syn). The levels of a-Syn are directly related to disease severity; with higher levels we see increased severity in both humans and model organisms. Based on these findings, lowering a-Syn levels will likely enable us to treat PD patients much better by stopping or slowing disease progression. It is difficult to suppress a-Syn directly, so we’re focusing on a protein that controls a-Syn levels, PFTAIRE protein kinase 1 (Pftk1), which can be targeted with traditional pharmaceuticals. When Pftk1 is inhibited a-Syn levels are reduced. A recently produced mouse model, completely lacking the gene to produce Pftk1, shows no sign of abnormalities which may indicate that chronic loss of Pftk1 would be safe for humans. Our first goal is to study these mice to confirm that chronic loss is safe and effective at lowering a-Syn levels. Our second goal is to determine whether partial loss of Pftk1 is sufficient to improve PD presentation by using a PD mouse model that contains half of the genes that produce Pftk1. This partial loss will be a better representation of what a pharmaceutical inhibition would look like. If these results are promising our next step will be to identify and test pharmaceutical Pftk1 inhibitors, with the ultimate goal of finding a medication for PD patients.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
O'Connor, Kaela
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~